Autologous CD34+ Cell Therapy for Ischemic Tissue Repair

Area of Science:

• Regenerative Medicine
• Vascular Biology
• Hematology

Background:

• The discovery of circulating bone marrow-derived cells in 1997 sparked debate on their role in neovascularization.
• Despite controversy, autologous CD34 cell therapy has emerged as a promising treatment for ischemic diseases.

Purpose of the Study:

• To review the preclinical and clinical evidence supporting autologous CD34 cell therapy.
• To consolidate findings from over 700 patients participating in CD34 cell therapy clinical trials.

Main Methods:

• Systematic review of preclinical studies on CD34 cell function in neovascularization.
• Analysis of clinical trial data from patients treated with autologous CD34 cells for various ischemic conditions.

Main Results:

• Preclinical data support the pro-angiogenic potential of CD34+ cells.
• Clinical trials demonstrate a consistent safety profile and significant clinical benefit in patients with ischemic conditions.

Conclusions:

• Autologous CD34 cell therapy is a safe and effective treatment for promoting neovascularization in ischemic diseases.
• The accumulated evidence supports the clinical utility of CD34 cell therapy in managing conditions characterized by insufficient blood supply.